07:00 Thu 31 Jan 2019
SkinBioTherapeutics - Update on human studies & IP portfolio extension
Interim update on human studies and extension of IP portfolio
SkinBioTherapeutics has completed testing on 60 of the total 120 volunteers for its human study, with no compliance or safety concerns. The final 60 volunteers are now being treated and the Company remains on track to complete the study during Q1 2019 as expected.
The study is double-blinded, meaning neither the volunteers nor the experimenters know who is receiving a particular treatment, to prevent any bias. For this reason, SkinBioTherapeutics will need the full dataset before it can be 'unblinded' for statistical analysis. The data will then be assessed to determine effectiveness - whether the SkinBiotix® technology retains the same beneficial property of improving skin health when in a cream formulation.
The resulting safety, irritancy and effectiveness data will be shared with potential global partners interested in commercialising the SkinBiotix® technology. A number of these companies have provided input into the study testing and analysis protocols.
In addition to the interim human study data, the Company has expanded its patent portfolio, with a patent proceeding to grant in
Dr
"We have now recruited all 120 volunteers and, at this mid-way point, there are no safety concerns. We remain on schedule to complete the human study during the first quarter of 2019.
"Being able to determine the potential for our SkinBiotix® technology as a clinically effective solution to improve skin health allows us to actively progress discussions with partners interested in commercialising the technology as a cosmetic.
"We are also determined to protect our intellectual property, hence the expansion of our patent portfolio."
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by
-ENDS-
For more information, please contact:
Dr.
|
Tel: +44 (0) 161 468 2760 |
|
Tel: +44 (0) 20 7213 0880 |
Turner Pope Investments (Joint Broker)
Dugald Carlean
|
Tel: +44 (0) 20 3621 4120
Tel: +44 (0) 20 3861 6625 |
|
Tel: +44 (0) 20 7457 2020 |
About
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr.
SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer office of the
The Company joined AIM in
The Company is based in
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE